Clinical Scorecard: Alopecia Associated with Isoniazid in Cases of Isoniazid-Monoresistant Pulmonary Tuberculosis
At a Glance
Category
Detail
Condition
Isoniazid-induced alopecia during anti-tuberculosis treatment
Key Mechanisms
Anagen effluvium caused by abrupt cessation of mitotic activity in hair matrix cells due to isoniazid
Target Population
Patients undergoing anti-tuberculosis treatment, particularly with isoniazid
Care Setting
Outpatient and inpatient settings managing tuberculosis treatment
Key Highlights
Alopecia is a rare but significant adverse drug reaction during anti-tuberculosis treatment, often leading to treatment discontinuation.
Isoniazid-induced alopecia typically presents as anagen effluvium with acute, reversible hair loss within 1–3 weeks of drug initiation.
Discontinuation of isoniazid leads to hair regrowth within approximately one month and requires regimen adjustment, especially in cases of isoniazid monoresistance.
Guideline-Based Recommendations
Diagnosis
Consider alopecia in patients on anti-tuberculosis treatment presenting with sudden hair loss.
Use clinical examination and exclude other causes such as thyroid dysfunction and infections.
Apply causality assessment tools like the Naranjo Adverse Drug Reaction Probability Scale.
Management
Discontinue isoniazid if alopecia is suspected to be drug-induced, especially with moderate to severe hair loss.
Substitute isoniazid with alternative agents such as moxifloxacin in cases of confirmed isoniazid monoresistance.
Continue other anti-tuberculosis drugs as per national guidelines for drug-resistant TB.
Monitoring & Follow-up
Monitor hair regrowth after discontinuation of the suspected drug.
Observe for other adverse drug reactions during treatment modification.
Regularly assess treatment adherence and psychological impact due to alopecia.
Risks
Discontinuation of isoniazid without appropriate substitution may lead to treatment failure or development of further drug resistance.
Psychological distress from alopecia may reduce patient adherence to anti-tuberculosis treatment.
Rechallenge or desensitization carries risk of severe or life-threatening reactions and is generally not recommended.
Patient & Prescribing Data
Young adults receiving first-line anti-tuberculosis treatment including isoniazid
Isoniazid-induced alopecia is reversible upon drug discontinuation; regimen adjustment with moxifloxacin is effective in managing isoniazid monoresistant TB.
Clinical Best Practices
Prompt recognition and diagnosis of alopecia as a potential adverse drug reaction during ATT.
Use of causality assessment scales to support clinical decision-making.
Timely discontinuation of the offending drug and substitution with effective alternatives.
Close monitoring of patient psychological well-being and adherence during treatment changes.
Reporting all adverse drug reactions to pharmacovigilance programs.
